Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare Triangle, Inc. filings document material-event reporting, shareholder voting matters, capital-structure changes, acquisition records, and governance disclosures for a healthcare information technology company. Recent 8-K filings cover the company’s Nasdaq-listed common stock, emerging growth company status, board-approved share repurchase program, and the completed reverse stock split reflected in amendments to its certificate of incorporation.
The filing record also includes proxy materials for a special stockholder meeting and material-agreement disclosures tied to subsidiary transactions. An amended 8-K provides acquired-business financial statements and pro forma financial information for Teyamé 360 S.L. and Datono Mediación S.L., connecting transaction disclosures with HCTI’s broader AI, digital health, and customer-engagement platform activity.
Healthcare Triangle, Inc. is offering 421,553 shares of common stock at a public offering price of $5.81 per share and is also offering up to 260,000 Pre-Funded Warrants to certain institutional investors to avoid post-closing ownership above 4.99% (or at purchaser election 9.99%).
The prospectus supplement shows 733,817 shares of Common Stock outstanding before this offering and, assuming full exercise of the Pre-Funded Warrants, 1,415,370 shares outstanding after this offering. Net proceeds are estimated at $3,682,635 before expenses. The offering is being placed by D. Boral Capital LLC and the securities are expected to be issued in a single closing.
Healthcare Triangle, Inc. enacted a 1‑for‑60 reverse stock split of its common stock effective at 12:01 a.m. Eastern Time on February 10, 2026. Every sixty issued and outstanding shares were combined into one share, leaving the number of authorized shares unchanged.
The split reduced issued and outstanding common shares from 45,417,091 to 756,984, with no fractional shares issued; any fractional position was rounded up to the next whole share. Proportional adjustments were made to outstanding warrants, stock options, convertible securities, and equity plan reserves.
The move is part of the company’s plan to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Healthcare Triangle’s common stock continues to trade on the Nasdaq Capital Market under the symbol HCTI and now carries a new CUSIP number, 42227W 405.
Healthcare Triangle, Inc. reported the results of its 2026 virtual Special Stockholders Meeting held on February 2, 2026. Stockholders voted on two proposals, each requiring approval by a majority of shares present and entitled to vote.
The company had 10,758,725 shares of common stock and 20,000 shares of Series A Super Voting preferred stock outstanding as of the January 8, 2026 record date, for a total of 20,409,725 voting shares. At the meeting, about 66.35% of these voting shares were represented, satisfying quorum requirements.
The first proposal received 20,231,200 votes for, 175,869 against, and 1,656 abstentions. The second proposal received 20,199,168 votes for, 203,557 against, and 7,000 abstentions. Both proposals were approved under the stated voting standard.
Healthcare Triangle, Inc. completed the acquisition of Spanish companies Teyamé 360 S.L. and Datono Mediación S.L. through its subsidiary, with a total purchase price of up to $50.0 million.
Consideration includes staged cash payments, $12.0 million in restricted common stock, and $18.0 million in preferred stock that is convertible into common stock based on a VWAP-derived Base Price, subject to shareholder approval and a 19.99% issuance cap using pre-funded warrants if needed.
The agreement also provides for an earnout of up to $5.0 million in preferred stock for key managers tied to 2026 and 2027 revenue and EBITDA targets, as well as potential purchase-price adjustments if post-closing financial results fall short of assumptions. The securities issued were unregistered, relying on a private-offering exemption.
Healthcare Triangle, Inc. is asking stockholders to approve a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-100, with the exact ratio to be chosen later by the Board. The company explains that the main goal is to increase its share price to help maintain compliance with Nasdaq’s $1.00 minimum bid price requirement and reduce the risk of delisting.
The reverse split would reduce the 10,758,725 shares of common stock outstanding as of January 8, 2026 in proportion to the final ratio, without changing each holder’s overall ownership percentage apart from rounding up fractional shares to the next whole share. Authorized common shares would not be reduced, effectively increasing the number available for future issuance. A second proposal asks stockholders to allow adjournment of the special meeting, if needed, to solicit more proxies in support of the reverse split.
Healthcare Triangle, Inc. (HCTI) has filed an S-3 prospectus covering the resale of 1,458,118 shares of common stock. These shares are issuable upon exercise of Inducement Warrants for 1,429,528 shares and Inducement Advisor Warrants for 28,590 shares that were issued in connection with an October 2025 warrant inducement transaction.
The company is not selling any shares in this prospectus and will not receive proceeds from Selling Stockholders’ resales. It may receive cash only if holders exercise the common warrants, which have a current exercise price of $3.00 per share, and could produce up to approximately $4.37 million in gross proceeds if fully exercised for cash.
The filing also explains that the new Inducement Warrants become exercisable after stockholder approval for issuances above 19.99% of outstanding common stock and include beneficial ownership caps of 4.99% or 9.99% to limit any single holder’s post-exercise ownership.
Healthcare Triangle, Inc. (HCTI) entered into a Securities Purchase Agreement with institutional investors for up to $15,000,000 in 20% original issue discount senior unsecured convertible notes. The first tranche closed on November 20, 2025, with an initial Note of $7,500,000 in principal sold for gross proceeds of approximately $6,000,000 and maturing on November 20, 2026.
The Notes are convertible at the holder’s option at a price equal to the greater of eighty percent of the lowest closing price over the five trading days before conversion or $0.38 per share. Undelivered conversion shares trigger liquidated damages of 2% of outstanding principal per month, and unpaid amounts bear interest at 18% per annum. A separate Registration Rights Agreement requires the company to register the resale of at least 300% of the maximum conversion shares by specific filing and effectiveness deadlines, with additional liquidated damages of 2% per month (capped at 20%) if deadlines are missed. RBW Capital Partners LLC acted as placement agent, earning an 8% cash fee on gross proceeds plus $100,000 for fees and expenses.
Healthcare Triangle, Inc. (HCTI) has filed a pre-effective amendment to register 1,458,118 shares of common stock for resale by existing security holders. These shares consist of 1,429,528 shares issuable upon exercise of inducement warrants and 28,590 shares issuable upon exercise of advisor warrants granted in connection with an October 2025 warrant inducement transaction. The company is not selling shares itself under this prospectus and will not receive proceeds from any resale, though it has already received $2.85 million from the prior warrant exercise and may receive additional cash if the new warrants are exercised at their $3.00 exercise price. If all common warrants are exercised, common stock outstanding would be 5,873,303 shares. The filing also highlights HCTI’s cloud, data, and AI-driven healthcare IT platforms and notes that adding freely tradable shares could pressure the stock price and dilute existing holders.
Healthcare Triangle, Inc. (HCTI) entered into a Sales Agreement with Spartan Capital Securities, LLC to sell shares of its common stock from time to time through an at-the-market offering program. The shares will be issued under an existing shelf registration statement on Form S-3, using a prospectus supplement dated November 18, 2025, with an aggregate market value of common stock currently eligible for sale of $20,000,000.
Spartan will act as sales agent and receive a 3.0% commission on the gross sales price of shares sold through it. Healthcare Triangle will control sale parameters such as number of shares, timing, daily limits, and minimum prices, and may suspend sales at any time. The agreement ends when all shares under the prospectus supplement are sold or if the agreement is otherwise terminated.